Cargando…
Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines
Background: COVID-19 vaccines induce a differentiated humoral and cellular response, and one of the comparable parameters of the vaccine response is the determination of IgG antibodies. Materials and Methods: Concentrations of IgG anti-SARS-CoV-2 antibodies were analyzed at three time points (at the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778136/ https://www.ncbi.nlm.nih.gov/pubmed/35062760 http://dx.doi.org/10.3390/vaccines10010099 |
_version_ | 1784637245534240768 |
---|---|
author | Szczepanek, Joanna Skorupa, Monika Goroncy, Agnieszka Jarkiewicz-Tretyn, Joanna Wypych, Aleksandra Sandomierz, Dorota Jarkiewicz-Tretyn, Aleksander Dejewska, Joanna Ciechanowska, Karolina Pałgan, Krzysztof Rajewski, Paweł Tretyn, Andrzej |
author_facet | Szczepanek, Joanna Skorupa, Monika Goroncy, Agnieszka Jarkiewicz-Tretyn, Joanna Wypych, Aleksandra Sandomierz, Dorota Jarkiewicz-Tretyn, Aleksander Dejewska, Joanna Ciechanowska, Karolina Pałgan, Krzysztof Rajewski, Paweł Tretyn, Andrzej |
author_sort | Szczepanek, Joanna |
collection | PubMed |
description | Background: COVID-19 vaccines induce a differentiated humoral and cellular response, and one of the comparable parameters of the vaccine response is the determination of IgG antibodies. Materials and Methods: Concentrations of IgG anti-SARS-CoV-2 antibodies were analyzed at three time points (at the beginning of May, at the end of June and at the end of September). Serum samples were obtained from 954 employees of the Nicolaus Copernicus University in Toruń (a total of three samples each were obtained from 511 vaccinated participants). IgG antibody concentrations were determined by enzyme immunoassay. The statistical analysis included comparisons between vaccines, between convalescents and COVID-19 non-patients, between individual measurements and included the gender, age and blood groups of participants. Results: There were significant differences in antibody levels between mRNA and vector vaccines. People vaccinated with mRNA-1273 achieved the highest levels of antibodies, regardless of the time since full vaccination. People vaccinated with ChAdOx1 nCoV-2019 produced several times lower antibody levels compared to the mRNA vaccines, while the antibody levels were more stable. In the case of each of the vaccines, the factor having the strongest impact on the level and stability of the IgG antibody titers was previous SARS-CoV-2 infection. There were no significant correlations with age, gender and blood type. Summary: mRNA vaccines induce a stronger humoral response of the immune system with the fastest loss of antibodies over time. |
format | Online Article Text |
id | pubmed-8778136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87781362022-01-22 Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines Szczepanek, Joanna Skorupa, Monika Goroncy, Agnieszka Jarkiewicz-Tretyn, Joanna Wypych, Aleksandra Sandomierz, Dorota Jarkiewicz-Tretyn, Aleksander Dejewska, Joanna Ciechanowska, Karolina Pałgan, Krzysztof Rajewski, Paweł Tretyn, Andrzej Vaccines (Basel) Article Background: COVID-19 vaccines induce a differentiated humoral and cellular response, and one of the comparable parameters of the vaccine response is the determination of IgG antibodies. Materials and Methods: Concentrations of IgG anti-SARS-CoV-2 antibodies were analyzed at three time points (at the beginning of May, at the end of June and at the end of September). Serum samples were obtained from 954 employees of the Nicolaus Copernicus University in Toruń (a total of three samples each were obtained from 511 vaccinated participants). IgG antibody concentrations were determined by enzyme immunoassay. The statistical analysis included comparisons between vaccines, between convalescents and COVID-19 non-patients, between individual measurements and included the gender, age and blood groups of participants. Results: There were significant differences in antibody levels between mRNA and vector vaccines. People vaccinated with mRNA-1273 achieved the highest levels of antibodies, regardless of the time since full vaccination. People vaccinated with ChAdOx1 nCoV-2019 produced several times lower antibody levels compared to the mRNA vaccines, while the antibody levels were more stable. In the case of each of the vaccines, the factor having the strongest impact on the level and stability of the IgG antibody titers was previous SARS-CoV-2 infection. There were no significant correlations with age, gender and blood type. Summary: mRNA vaccines induce a stronger humoral response of the immune system with the fastest loss of antibodies over time. MDPI 2022-01-10 /pmc/articles/PMC8778136/ /pubmed/35062760 http://dx.doi.org/10.3390/vaccines10010099 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Szczepanek, Joanna Skorupa, Monika Goroncy, Agnieszka Jarkiewicz-Tretyn, Joanna Wypych, Aleksandra Sandomierz, Dorota Jarkiewicz-Tretyn, Aleksander Dejewska, Joanna Ciechanowska, Karolina Pałgan, Krzysztof Rajewski, Paweł Tretyn, Andrzej Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
title | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
title_full | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
title_fullStr | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
title_full_unstemmed | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
title_short | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
title_sort | anti-sars-cov-2 igg against the s protein: a comparison of bnt162b2, mrna-1273, chadox1 ncov-2019 and ad26.cov2.s vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778136/ https://www.ncbi.nlm.nih.gov/pubmed/35062760 http://dx.doi.org/10.3390/vaccines10010099 |
work_keys_str_mv | AT szczepanekjoanna antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT skorupamonika antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT goroncyagnieszka antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT jarkiewicztretynjoanna antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT wypychaleksandra antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT sandomierzdorota antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT jarkiewicztretynaleksander antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT dejewskajoanna antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT ciechanowskakarolina antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT pałgankrzysztof antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT rajewskipaweł antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT tretynandrzej antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines |